We are live on ! Find out more
ELDN icon

Eledon Pharmaceuticals
ELDN

27 hedge funds and large institutions have $76.8M invested in Eledon Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 27 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
27
Holders Change
+27
Holders Change %
–
% of All Funds
0.78%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
+$18.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$10.1M
3
TCP
Tourbillon Capital Partners
New York
+$8.42M
4
RG
Redmile Group
California
+$7.27M
5
Franklin Resources
Franklin Resources
California
+$7.02M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
MAA
26
Managed Account Advisors
New Jersey
$3K +$2.84K +1 New
TRCT
27
Tower Research Capital (TRC)
New York
$3K +$2.84K +1 New
1
2

ELDN Hedge Fund Activity: Q3 2014 in Review

27 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q3 2014, worth a combined $76.8M.

Buyers outnumbered sellers: 27 funds opened new ELDN positions and 0 closed out — a net gain of 27 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $18.9M.

  • 27 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q3 2014, up from 0 in Q2 2014.
  • Funds reported $76.8M of Eledon Pharmaceuticals stock for Q3 2014.
  • 27 funds opened new Eledon Pharmaceuticals positions in Q3 2014 and 0 closed out, a net change of +27 holders.
  • The largest Eledon Pharmaceuticals buyer in Q3 2014 was Novo Holdings A/S, an estimated $18.9M added.

Based on aggregated 13F filings for Q3 2014.